SomnoMed posts record half-year revenue and boosts manufacturing capacity

An announcement from Somnomed Limited ( (AU:SOM) ) is now available.

SomnoMed reported record first-half FY26 revenue of $60.7 million, up 13% year on year, driven by double-digit growth in Europe and North America and stable margins at 61.3%. EBITDA rose 35% to $7.8 million as the company leveraged operating efficiencies while deferring some planned spending to the second half.

The group increased capital expenditure to $3.4 million to expand manufacturing capacity by more than 20%, aiming to meet peak demand while reducing reliance on overtime. Net cash improved to $17.3 million, and management reaffirmed full-year guidance for revenue of $119–126 million and EBITDA of $10–12 million, signalling confidence in sustained growth and operational resilience.

The most recent analyst rating on (AU:SOM) stock is a Hold with a A$0.74 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.

More about Somnomed Limited

SomnoMed Limited is a medical device company specialising in oral appliance treatments for sleep-related breathing disorders, particularly obstructive sleep apnea. The business focuses on custom-made oral devices as an alternative to CPAP therapy, with a strong presence in Europe and North America where reimbursement frameworks support adoption.

Average Trading Volume: 125,019

Technical Sentiment Signal: Sell

Current Market Cap: A$150.7M

Find detailed analytics on SOM stock on TipRanks’ Stock Analysis page.